Journal of Psychosomatic Research
Volume 67, Issue 6 , Pages 575-584 , December 2009

Functional neuroimaging in Tourette syndrome

  • Hugh Rickards

      Affiliations

    • Corresponding Author InformationDepartment of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Barberry Building, 25 Vincent Drive, Edgbaston, Birmingham B15 2FG, UK.

Received 24 April 2009 ,Revised 24 June 2009 ,Accepted 28 July 2009.

References 

  1. Stefan H, Pawlick G, Bocher-Schwarz HG, et al. Functional and morphological abnormalities temporal lobe epilepsy: a comparison of interictal and ictal EEG. J Neurol. 2007;134:377–384
  2. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in post-mortem striatum from patient's with Tourette syndrome. Ann Neurol. 1991;30:558–562
  3. Turjanski N, Sawle G, Playford ED, et al. PET studies of presynaptic and postsynaptic dopaminergic system in Tourette syndrome. J Neurol Neurosurg Psychiatry. 1994;57:688–692
  4. Brooks DJ, Turjanski N, Sawle GV, et al. PET studies on the integrity of the pre- and post-synaptic dopaminergic system in Tourette syndrome. Adv Neurol. 1992;58:233–239
  5. Ernst M, Zametkin A, Jons P, et al. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:85–94
  6. Wong DF, Singer HS, Brandt J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med. 1997;38:1243–1247
  7. Wong DF, Brasic JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–1251
  8. Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry. 2002;159:1329–1336
  9. Gilbert DL, Christian BT, Gelfand MJ, et al. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology. 2006;67:1695–1697
  10. Wolf SS, Jones DW, Knable MB, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1225–1227
  11. Müller-Vahl KR, Berding G, Kolbe H, et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand. 2000;101:165–171
  12. Malinson RT, McDougle CJ, van Dyck CH, et al. [123I] β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry. 1995;152:1359–1361
  13. Heinz A, Knable MB, Wolf SS, et al. Tourette's syndrome. [I-123] β-CIT SPECT correlates of vocal tic severity. Neurology. 1998;51:1069–1074
  14. Stamenkovic M, Schindler U, de Zwaan M, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [123I]beta-CIT SPECT study. Eur Neuropsychopharmacol. 2001;11:69–74
  15. Müller-Vahl KR, Berding G, Brücke T, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol. 2000;247:514–520
  16. Serra-Mestres J, Ring HA, Costa DC, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I] FP-CIT/SPECT study. Acta Psychiatr Scand. 2004;109:140–146
  17. Cheon KA, Ryu YH, Namkoong K, et al. Dopamine transporter density of the basal ganglia assessed with [123I]PT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res Neuroimaging. 2004;130:85–95
  18. Mena I, Miranda M, Hernandez M, et al. Dopamine transporter imaging in Tourette syndrome: evaluation by neuroSPECT of Trodat 1-Tc99m. Mov Disord. 2004;19:1282
  19. Hwang WJ, Yao WJ, Fu YK, Yang AS. [99mTc] TRODAT-1/ [123I] IBZM SPECT studies of the dopaminergic system in Tourette syndrome. Psychiatry Res Imaging. 2008;162:159–166
  20. Yeh CB, Lee CS, Ma KH, et al. Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging. Psychiatry Res Imaging. 2007;156:75–82
  21. Bohnen NI, Minoshima S, Kilbourn MR, et al. Presynaptic monoaminergic vesicular transporter imaging in Tourette syndrome using (+)-[alpha]-[11C]DTBZ PET. Neurology. 1999;52:A176
  22. Albin RL, Koeppe RA, Bohnen NI, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315
  23. Albin RL, Koeppe RA, Wernette K, et al. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72:1390–1396
  24. Berding G, Müller-Vahl K, Schneider U, et al. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole body scanning for radiation dose in Tourette patients. Biol Psychiatry. 2004;55:904–915
  25. Behen M, Chugani HT, Juhasz C, et al. Abnormal brain tryptophan metabolism and clinical correlates in Tourette syndrome. Mov Disord. 2007;22:2256–2262
  26. Haugbol S, Pinborg LH, Regeur L, et al. Cerebral 5-HT2A binding is increased in patients with Tourette syndrome. Int J Neuropsychopharmacol. 2007;10:245–252
  27. Podreka I, Suess E, Goldenberg G, et al. Initial experience with technetium-99m-HM-PAO brain SPECT. J Nucl Med. 1987;28:1657–1666
  28. George MS, Trimble MR, Costa DC, et al. Elevated frontal cerebral blood flow in Gilles de la Tourette syndrome: a 99Tcm-HMPAO study. Psychiatry Res. 1992;45:143–151
  29. Riddle MA, Rasmusson AM, Woods SW, et al. SPECT imaging of cerebral blood flow in Tourette syndrome. Adv Neurol. 1992;58:207–211
  30. Moriarty J, Campos Costa D, Schmitz B, et al. Brain perfusion abnormalities in Gilles de la Tourette's syndrome. Br J Psychiatry. 1995;16:249–254
  31. Kleiger PS, Fett KA, Dimitsopulos T, Kurlan R. Asymmetry of basal ganglia perfusion in Tourette's syndrome shown by technetium-99m-HMPAO SPECT. J Nucl Med. 1997;38:188–191
  32. Chiu NT, Chang YC, Lee BF, et al. Differences in 99mTc-HMPAO brain SPET perfusion imaging between Tourette's syndrome and chronic tic disorder in children. Eur J Nucl Med. 2001;28:183–190
  33. Moriarty J, Eapen V, Costa DC, et al. HMPAO SPET does not distinguish obsessive–compulsive and tic syndromes in families multiply affected with Gilles de la Tourette's syndrome. Psychol Med. 1997;27:737–740
  34. Sieg KG, Buckingham D, Gaffney G, et al. Tc-99m HMPAO SPECT brain imaging of Gilles de la Tourette syndrome. Clin Nucl Med. 1993;18:255
  35. Diler SD, Reyhanli M, Toros F, et al. Tc-99m-ECD SPECT brain imaging in children with Tourette's syndrome. Yonsei Med J. 2002;43:403–410
  36. Chase TN, Foster NL, Fedio P, et al. Gilles de la Tourette syndrome: studies with fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method. Ann Neurol. 1984;15:S175
  37. Brooks RA, Friauf WS, Sank VJ, et al. Initial evaluation of a high resolution positron emission tomography. In:  Greitz T,  Ingvar D,  Wilden L editor. The metabolism of the human brain studied with positron emission tomography. New York: Raven Press; 1985;p. 57–68
  38. Braun AR, Stoetter B, Randolph C. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study: I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993;9:277–291
  39. Stoetter B, Braun AR, Randolph C, et al. Functional neuroanatomy of Tourette syndrome. Limbic–motor interactions studied with FDG PET. Adv Neurol. 1992;58:213–225
  40. Eidelberg D, Moeller JR, Antonini A, et al. The metabolic anatomy of Tourette syndrome. Neurology. 1997;48:927–934
  41. Stern E, Silbersweig DA, Chee KY, et al. A functional neuroanatomy of Tourette syndrome. Arch Gen Psychiatry. 2000;57:741–748
  42. Lerner A, Bagic A, Boudreau EA, et al. Neuroimaging of neuronal circuits involved in tic generation in patients with Tourette syndrome. Neurology. 2007;68:1979–1987
  43. Jeffries KJ, Schooler C, Schoenbach C, et al. The functional neuroanatomy of Tourette's syndrome: an FG PET study: III. Functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology. 2002;27:92–104
  44. Peterson B, Skudarlski P, Anderson AW, et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry. 1998;54:326–333
  45. Biswal B, Ulmer JL, Krippendorf R, et al. Abnormal cerebral activation associated with a motor task in Tourette syndrome. Am J Neuroradiol. 1998;19:1509–1512
  46. Hershey T, Black K, Hartlein JM, et al. Cognitive–pharmacologic functional magnetic resonance imaging in Tourette syndrome: a pilot study. Biol Psychiatry. 2004;55:916–925
  47. Gates L, Clarke J, Stokes A, et al. Neuroanatomy of coprolalia in Tourette syndrome using functional magnetic resonance imaging. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28:397–400
  48. Fattaposta F, Restucccia R, Colonnese C, et al. Gilles de la Tourette syndrome and voluntary movement: a functional MRI study. Psychiatry Res Neuroimaging. 2005;138:269–272
  49. Marsh R, Zhu H, Wang Z. A developmental fMRI study of self-regulatory control in Tourette's syndrome. Am J Psychiatry. 2007;164:955–966
  50. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643–662
  51. Bohlhalter S, Goldfine A, Matteson S, et al. Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study. Brain. 2006;129:2029–2037
  52. Baym CL, Corbett BA, Wright SB, et al. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain. 2008;131:165–179
  53. Church JA, Fair DA, Dosenbach NUF, et al. Control networks in paediatric Tourette syndrome show immature and anomalous patterns. Brain. 2009;132:225–238
  54. Mink J. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns. Adv Neurol. 2001;85:113–123

PII: S0022-3999(09)00323-7

doi: 10.1016/j.jpsychores.2009.07.024

Journal of Psychosomatic Research
Volume 67, Issue 6 , Pages 575-584 , December 2009

Article Tools